B of A Securities Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $45
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsInitiationPrice Target
B of A Securities analyst Tazeen Ahmad initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Buy rating and announces Price Target of $45.
B of A Securities analyst Tazeen Ahmad initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Buy rating and announces Price Target of $45.